U.S. COMPANY FILING
ABBOTT LABORATORIES — Form 10-Q filed 2026-07-28
Filing text preview
Abbott's Q2 2026 net earnings were $928M, down from $1,779M in Q2 2025. The company completed the $20.6B acquisition of Exact Sciences, entering cancer diagnostics. Total sales were $9.49B in Q2 and $23.76B in H1. The acquisition was funded with $20B in new debt, significantly increasing long-term debt. Legal risks include NEC lawsuits with potential losses up to $530M.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record